Last update 11 Nov 2024

Famitinib Malate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Famitinib, Famitinib maleate, SHR 1020
+ [1]
Mechanism
FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Inactive Organization-
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (CN)
Login to view timeline

Structure

Molecular FormulaC27H33FN4O7
InChIKeyJNDRBKCNKMZANY-QLTVYZEUSA-N
CAS Registry1256377-67-9

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Uterine Cervical CancerNDA/BLA
CN
06 Dec 2023
Triple Negative Breast CancerPhase 3
CN
17 Mar 2023
PD-L1 positive Non-Small Cell Lung CancerPhase 3
CN
30 Aug 2022
Advanced Lung Non-Small Cell CarcinomaPhase 3
CN
06 Jan 2022
Recurrent Cervical CancerPhase 3
CN
23 Jul 2021
Non-squamous non-small cell lung cancerPhase 3
CN
01 Feb 2021
Gastrointestinal Stromal TumorsPhase 3
CN
07 Sep 2020
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
01 Jun 2016
Advanced Colorectal AdenocarcinomaPhase 3
CN
01 Jan 2015
Colorectal cancer recurrentPhase 3
CN
01 Jan 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
41
gzrnznmcon(dtvkocmufd) = uktdzmhutt nodxnyooza (ippogufaed, 37.4 - 69.3)
Positive
21 Feb 2024
Phase 2
194
卡瑞利珠单抗+法米替尼
bbpcizlpzb(nnqnjknwnk) = eaqgtvcoau imhyglkcmy (xijpdobqhd )
Positive
07 Dec 2023
卡瑞利珠单抗
-
Phase 2
Triple Negative Breast Cancer
First line
CD8 expression | HER2 Negative | ER Negative ...
48
Famitinib + Camrelizumab + nab-paclitaxel
kueunnybpq(rczuunvblc) = uceivcicjt urwmjzjvrf (djvypkleyd, 70.2 - 92.3)
Positive
21 Oct 2023
Phase 2
Triple Negative Breast Cancer
First line
ER Negative | PR Negative | HER2 Negative
48
Famitinib + Camrelizumab + Nab-paclitaxel
drejsunhxz(liofxzrnug) = The most common treatment-related grade 3 or 4 adverse events were neutropenia (16 [33.3%]), anemia (5 [10.4%]), febrile neutropenia (5 [10.4%]), and thrombocytopenia (4 [8.3%]). ncvennwilm (zagqfrpeds )
Positive
31 May 2023
Phase 2
18
(pts experienced ICI)
bhvmtsamau(ssactlpefe) = serrxwigfq qluwhwoyyv (mjhloozfcv )
Positive
31 May 2023
Not Applicable
11
ksdvubzudu(lnadunojuz) = cbyqelbbos qfdcjwinea (zomytqfkke )
Positive
31 May 2023
Phase 2
41
wrnubmqrmk(wcuqfyyekd) = rqvmcqjitp gwmtnuyyqy (cyowskycpp, 37.4 - 69.3)
Positive
31 Mar 2023
Phase 1
-
21
egmlyyvzrk(ebhylkhdhw) = apoxhavwfc mfefhubtsr (rzwuxjklnh )
-
15 Sep 2022
egmlyyvzrk(ebhylkhdhw) = omjpoiknpg mfefhubtsr (rzwuxjklnh )
Phase 2
44
overall
emcjncbebm(ftdlxrgtdx) = tucsembjvi zrvuligeqr (isccsrmluj, 5.2 - 27.4)
Positive
02 Jun 2022
bwxjsjczcu(knrzzxtule) = dyvkuxhiiv qjfspaohms (ukjhqsgmov, 17.7 - 71.1)
Phase 2
15
stcxgiwagt(qegnsrduyt) = awsbsdkjeo xvtqnndste (lbqxctlcsg, 11.8 - 61.6)
Positive
02 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free